Blood Telomere Length Attrition and Cancer Development in the Normative Aging Study Cohort

EBioMedicine

Volumn 2, Issue 6, 2015, Pages 591-596

  Hou, Lifang ^a   Joyce, Brian Thomas ^a,b   Gao, Tao ^a   Liu, Lei ^a   Zheng, Yinan ^a   Penedo, Frank J ^a   Liu, Siran ^c   Zhang, Wei ^a   Bergan, Raymond ^a   Dai, Qi ^d   Vokonas, Pantel ^e,f   Hoxha, Mirjam ^g   Schwartz, Joel ^h   Baccarelli, Andrea ^h  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c Northwestern University   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e VA BOSTON HEALTHCARE SYSTEM   (United States)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF MILAN   (Italy)

^h HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cancer incidence; Longitudinal study; Telomere

Indexed keywords

DNA; TUMOR MARKER;

AGE; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD TELOMERE LENGTH; CANCER GROWTH; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; EDUCATIONAL STATUS; ETHNICITY; GENE DOSAGE; GENETIC ASSOCIATION; HUMAN; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; QUESTIONNAIRE; REAL TIME POLYMERASE CHAIN REACTION; TELOMERE HOMEOSTASIS; AGING; LEUKOCYTE; LONGITUDINAL STUDY; MIDDLE AGED; NEOPLASMS; PATHOPHYSIOLOGY; PHYSIOLOGY; TELOMERE; TELOMERE SHORTENING; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; BIOMARKERS, TUMOR; COHORT STUDIES; HUMANS; LEUKOCYTES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; TELOMERE; TELOMERE HOMEOSTASIS; TELOMERE SHORTENING;

EID: 84948769565     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.04.008     Document Type: Article

References (34)

1. Aviv A., Levy D. Telomeres, atherosclerosis, and the hemothelium: the longer view. Annu. Rev. Med. 2012, 63:293-301.
2. Bryan T.M., Englezou A., Gupta J., Bacchetti S., Reddel R.R. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J. 1995, 14(17):4240-4248.
3. Cawthon R.M. Telomere measurement by quantitative PCR. Nucleic Acids Res. 2002, 30(10):e47.
4. Chakraborty S., Sun C.L., Francisco L., et al. Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. J. Clin. Oncol. 2009, 27(5):791-798.
5. DePinho R.A. The age of cancer. Nature 2000, 408(6809):248-254.
6. Frias C., Pampalona J., Genesca A., Tusell L. Telomere dysfunction and genome instability. Front. Biosci. 2012, 17:2181-2196.
7. Giaimo S., d'Adda di Fagagna F. Is cellular senescence an example of antagonistic pleiotropy?. Aging Cell 2012, 11(3):378-383.
8. Hackett J.A., Greider C.W. Balancing instability: dual roles for telomerase and telomere dysfunction in tumorigenesis. Oncogene 2002, 21(4):619-626.
9. Hodes R.J., Hathcock K.S., Weng N.P. Telomeres in T and B cells. Nat. Rev. Immunol. 2002, 2(9):699-706.
10. Hou L., Savage S.A., Blaser M.J., et al. Telomere length in peripheral leukocyte DNA and gastric cancer risk. Cancer Epidemiol. Biomarkers Prev. 2009, 18(11):3103-3109.
11. Hou L., Zhang X., Gawron A.J., Liu J. Surrogate tissue telomere length and cancer risk: shorter or longer?. Cancer Lett. 2012, 319(2):130-135.
12. Hou L., Wang S., Dou C., et al. Air pollution exposure and telomere length in highly exposed subjects in Beijing, China: a repeated-measure study. Environ. Int. 2012, 48:71-77.
13. Hug N., Lingner J. Telomere length homeostasis. Chromosoma 2006, 115(6):413-425.
14. Hurwitz L.M., Heaphy C.M., Joshu C.E., et al. Telomere length as a risk factor for hereditary prostate cancer. Prostate 2014, 74(4):359-364.
15. Ichikawa M., Williams R., Wang L., Vogl T., Srikrishna G. S100A8/A9 activate key genes and pathways in colon tumor progression. Mol. Cancer Res. 2011, 9(2):133-148.
16. Jennings B.J., Ozanne S.E., Hales C.N. Nutrition, oxidative damage, telomere shortening, and cellular senescence: individual or connected agents of aging?. Mol. Genet. Metab. 2000, 71(1-2):32-42.
17. Kong C.M., Lee X.W., Wang X. Telomere shortening in human diseases. FEBS J. 2013, 280(14):3180-3193.
18. Londono-Vallejo J.A. Telomere instability and cancer. Biochimie 2008, 90(1):73-82.
19. Lu L., Zhang C., Zhu G., et al. Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome. Breast Cancer Res. 2011, 13(3):R56.
20. Lundblad V., Szostak J.W. A mutant with a defect in telomere elongation leads to senescence in yeast. Cell 1989, 57(4):633-643.
21. Ma H., Zhou Z., Wei S., et al. Shortened telomere length is associated with increased risk of cancer: a meta-analysis. PLoS One 2011, 6(6):e20466.
22. Meeker A.K. Telomeres and telomerase in prostatic intraepithelial neoplasia and prostate cancer biology. Urol. Oncol. 2006, 24(2):122-130.
23. Meeker A.K., Hicks J.L., Platz E.A., et al. Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Res. 2002, 62(22):6405-6409.
24. Mirabello L., Huang W.Y., Wong J.Y., et al. The association between leukocyte telomere length and cigarette smoking, dietary and physical variables, and risk of prostate cancer. Aging Cell 2009, 8(4):405-413.
25. Ornish D., Lin J., Daubenmier J., et al. Increased telomerase activity and comprehensive lifestyle changes: a pilot study. Lancet Oncol. 2008, 9(11):1048-1057.
26. Sampedro Camarena F., Cano Serral G., Sampedro Santalo F. Telomerase and telomere dynamics in ageing and cancer: current status and future directions. Clin. Transl. Oncol. 2007, 9(3):145-154.
27. Schnekenburger J., Schick V., Kruger B., et al. The calcium binding protein S100A9 is essential for pancreatic leukocyte infiltration and induces disruption of cell-cell contacts. J. Cell. Physiol. 2008, 216(2):558-567.
28. Shay J.W., Zou Y., Hiyama E., Wright W.E. Telomerase and cancer. Hum. Mol. Genet. 2001, 10(7):677-685.
29. Sidorov I., Kimura M., Yashin A., Aviv A. Leukocyte telomere dynamics and human hematopoietic stem cell kinetics during somatic growth. Exp. Hematol. 2009, 37(4):514-524.
30. Unryn B.M., Hao D., Gluck S., Riabowol K.T. Acceleration of telomere loss by chemotherapy is greater in older patients with locally advanced head and neck cancer. Clin. Cancer Res. 2006, 12(21):6345-6350.
31. von Zglinicki T. Oxidative stress shortens telomeres. Trends Biochem. Sci. 2002, 27(7):339-344.
32. Weischer M., Nordestgaard B.G., Cawthon R.M., Freiberg J.J., Tybjaerg-Hansen A., Bojesen S.E. Short telomere length, cancer survival, and cancer risk in 47102 individuals. J. Natl. Cancer Inst. 2013, 105(7):459-468.
33. Willeit P., Willeit J., Mayr A., et al. Telomere length and risk of incident cancer and cancer mortality. JAMA 2010, 304(1):69-75.
34. Zhu Z.Z., Sparrow D., Hou L., et al. Repetitive element hypomethylation in blood leukocyte DNA and cancer incidence, prevalence, and mortality in elderly individuals: the Normative Aging Study. Cancer Causes Control 2011, 22(3):437-447.